selinexor + azacitidine

A combination therapy consisting of the selective inhibitor of nuclear export (SINE) selinexor and the hypomethylating agent azacitidine. Selinexor is a first-in-class, oral small molecule that covalently binds to and inhibits Exportin 1 (XPO1), a protein responsible for the nuclear-to-cytoplasmic export of tumor suppressor proteins and growth-regulatory factors. By blocking XPO1, selinexor promotes the nuclear accumulation and activation of tumor suppressors, leading to apoptosis in malignant cells. Azacitidine is a pyrimidine nucleoside analog that acts as a DNA methyltransferase inhibitor; it incorporates into DNA and RNA, causing DNA hypomethylation and direct cytotoxicity, which helps restore normal hematopoiesis. This combination is being investigated as a maintenance therapy for patients with TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplantation to reduce the high risk of relapse in this specific molecular subpopulation.

Other names

selinexor and azacitidineazacitidine and selinexor